Publication | Closed Access

Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux

Cellular Cholesterol EffluxBreast OncologyOxysterolBiochemistryMedicinePharmacologyEicosapentaenoic AcidBreast CancerTriple-negative Breast CancerAnti-cancer AgentOncologyTumor Biology